BGLC · NASDAQ
BioNexus Gene Lab (BGLC) Stock Price & Fundamentals
BioNexus Gene Lab (BGLC) closed at $462.65 on Oct 9, 2026, down 0.90% from the previous close of $466.83.
Share price, past year
1Y +20.78%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $462.65 |
| Sep 30, 2026 | $470.66 |
| Aug 31, 2026 | $488.81 |
| Jul 31, 2026 | $477.51 |
| Jun 30, 2026 | $495.74 |
| May 29, 2026 | $483.30 |
| Apr 30, 2026 | $479.34 |
| Mar 31, 2026 | $450.46 |
| Feb 27, 2026 | $449.23 |
| Jan 30, 2026 | $431.80 |
| Dec 31, 2025 | $408.65 |
| Nov 28, 2025 | $394.47 |
| Oct 31, 2025 | $377.92 |
Key statistics
- Market cap
- $1.12B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- $3.13M
- Net income (TTM)
- −$2.58M
- Shares outstanding
- 2.4M
- Dividend yield
- —
- 52-week range
- $369.45 – $511.34
BioNexus Gene Lab's market cap is $1.12B, based on a share price of $462.65 and 2.4M shares outstanding as of Jun 30, 2026.
Financials
BioNexus Gene Lab reported revenue of $7.42M for fiscal 2025, down 21.93% from fiscal 2024.
BioNexus Gene Lab reported a net loss of $2.98M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $7.42M | −21.9% | −$2.98M | −40.2% | — | −$1.88M |
| FY2024ended Dec 31, 2024 | $9.51M | −2.7% | −$1.60M | −16.8% | −$0.09 | −$2.32M |
| FY2023ended Dec 31, 2023 | $9.77M | −10.6% | −$2.63M | −26.9% | −$0.166 | −$1.97M |
| FY2022ended Dec 31, 2022 | $10.93M | −18.2% | −$355.97K | −3.3% | — | $551.82K |
| FY2021ended Dec 31, 2021 | $13.36M | +17.3% | $751.57K | 5.6% | — | $6.00K |
| FY2020ended Dec 31, 2020 | $11.39M | +8,872.0% | $1.09M | 9.6% | — | $131.06K |
| FY2019ended Dec 31, 2019 | $126.96K | −40.2% | −$246.47K | −194.1% | — | −$230.09K |
| FY2018ended Dec 31, 2018 | $212.33K | — | $26.45K | 12.5% | — | −$234.46K |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $76.16K | −$286.45K | −$0.118 |
| Q1 FY2026ended Mar 31, 2026 | $22.84K | −$543.58K | −$0.225 |
| Q4 FY2025ended Dec 31, 2025 | $483.76K | −$1.04M | — |
| Q3 FY2025ended Sep 30, 2025 | $2.54M | −$708.99K | −$0.395 |
| Q2 FY2025ended Jun 30, 2025 | $2.26M | −$616.17K | −$0.343 |
| Q1 FY2025ended Mar 31, 2025 | $2.14M | −$623.33K | −$0.347 |
| Q4 FY2024ended Dec 31, 2024 | $2.52M | −$348.32K | — |
| Q3 FY2024ended Sep 30, 2024 | $2.63M | −$1.35M | −$0.749 |
Company profile
- Name
- BioNexus Gene Lab Corp
- Ticker
- BGLC
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Services-Medical Laboratories
- Headquarters
- Unit A-28-7, Tower A, Menara Uoa Bangsar, No. 5 Jln Bangsar Utama 1, Kuala Lumpur, 59000
- Incorporated in
- WY
- Fiscal year ends
- December
- SEC CIK
- 0001737523
Recent SEC filings
- Oct 7, 2026
- Aug 14, 2026
- Jul 28, 2026
- Jun 5, 2026
- May 15, 2026
- Apr 14, 2026
- Mar 17, 2026
- Feb 23, 2026
Frequently asked questions
What is BioNexus Gene Lab's stock price?
BioNexus Gene Lab (BGLC) closed at $462.65 on Oct 9, 2026, down 0.90% from the previous close of $466.83.
What is BioNexus Gene Lab's market cap?
BioNexus Gene Lab's market cap is $1.12B, based on a share price of $462.65 and 2.4M shares outstanding as of Jun 30, 2026.
How much revenue does BioNexus Gene Lab make?
BioNexus Gene Lab reported revenue of $7.42M for fiscal 2025, down 21.93% from fiscal 2024.
Does BioNexus Gene Lab pay a dividend?
BioNexus Gene Lab's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from BioNexus Gene Lab Corp's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures